Search

Now showing items 1-10 of 40

Duration of immune protection of SARS-CoV-2 natural infection against reinfection.

Chemaitelly, Hiam; Nagelkerke, Nico; Ayoub, Houssein H; Coyle, Peter; Tang, Patrick; ... more authors ... less authors ( Oxford University Press , 2022 , Article)

The future of the SARS-CoV-2 pandemic hinges on virus evolution and duration of immune protection of natural infection against reinfection. We investigated duration of protection afforded by natural infection, the effect ...

Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.

Altarawneh, Heba N; Chemaitelly, Hiam; Ayoub, Houssein H; Tang, Patrick; Hasan, Mohammad R; ... more authors ... less authors ( Massachusetts Medical Society , 2022 , Article)

The protection conferred by natural immunity, vaccination, and both against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the BA.1 or BA.2 sublineages of the omicron (B.1.1.529) ...

Effects of BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2 omicron infections.

Qassim, Suelen H; Chemaitelly, Hiam; Ayoub, Houssein H; AlMukdad, Sawsan; Tang, Patrick; ... more authors ... less authors ( Oxford University Press , 2022 , Article)

Compared to BA.1, BA.2 was associated with lower RT-qPCR cycle threshold (Ct) value-3.53 fewer cycles (95% CI: 3.46-3.60), signifying higher infectiousness. This may reflect higher viral load and/or longer duration of ...

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.

Chemaitelly, Hiam; Ayoub, Houssein H; AlMukdad, Sawsan; Coyle, Peter; Tang, Patrick; ... more authors ... less authors ( Nature Research , 2022 , Article)

SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 ...

SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar.

Al-Thani, Mohamed H; Farag, Elmoubasher; Bertollini, Roberto; Al Romaihi, Hamad Eid; Abdeen, Sami; ... more authors ... less authors ( Oxford University Press , 2021 , Article)

Qatar experienced a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic that disproportionately affected the craft and manual worker (CMW) population, who comprise 60% of the total population. This study ...

Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections.

Abu-Raddad, Laith J; Chemaitelly, Hiam; Ayoub, Houssein H; Tang, Patrick; Coyle, Peter; ... more authors ... less authors ( Springer , 2022 , Article)

SARS-CoV-2 breakthrough infections in vaccinated individuals and in those who had a prior infection have been observed globally, but the transmission potential of these infections is unknown. The RT-qPCR cycle threshold ...

Comparison of antibody immune responses between BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in naïve and previously infected individuals.

Al-Sadeq, Duaa W; Shurrab, Farah M; Ismail, Ahmed; Amanullah, Fathima Humaira; Thomas, Swapna; ... more authors ... less authors ( Oxford University Press , 2021 , Article)

Two mRNA vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, obtained the Emergency Use Listing by WHO for preventing COVID-19. However, little is known about the difference in antibody responses induced by these two mRNA ...

Low risk of serological cross-reactivity between the dengue virus and SARS-CoV-2 IgG antibodies using advanced detection assays.

Shurrab, Farah M; Al-Sadeq, Duaa W; Amanullah, Fatima Humaira; Al-Absi, Enas S; Qotba, Hamda; ... more authors ... less authors ( Karger , 2022 , Report)

Several studies have reported serological cross-reactivity of the immune responses between SARS-CoV-2 and DENV. Most of the available studies are based on the point of care (POC) rapid testing kits. However, some rapid ...

Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.

Abu-Raddad, Laith J; Chemaitelly, Hiam; Ayoub, Houssein H; AlMukdad, Sawsan; Yassine, Hadi M; ... more authors ... less authors ( Massachusetts Medical Society , 2022 , Article)

Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to expedited ...

Level of Maternal Respiratory Syncytial Virus (RSV) F Antibodies in Hospitalized Children and Correlates of Protection.

Taleb, Sara A; Al-Ansari, Khalid; Nasrallah, Gheyath K; Elrayess, Mohamed A; Al-Thani, Asmaa A; ... more authors ... less authors (2021)

RSV is a major cause of lower respiratory infections among children, where no vaccine is available. The stabilized form of the fusion (F) protein, pre-F, is a leading vaccine candidate targeting different populations, ...